Docencia
Doravirine versus ritonavir-boosted darunavir in antiretroviral-naive adults HIV-1 (DRIVE-FORWARD): 48- week results of a randomised, double-blind, phase 3, non inferiority trial (15-06-2018)
Dr. Julián Olalla Sierra. Especialista en Medicina Interna Hospital Costa del Sol, Marbella
Post-exposure prophylaxis with doxycycline to prevent sexually transmitted infections in men who have sex with men: an open-label randomised substudy of the ANRS IPERGAY trial (01-06-2018)
Dra. Marta Montero Alonso. Unidad de Enfermedades Infecciosas. Hospital Universitario y Politécnico la Fe, Valencia.
Recent Abacavir Use Increases Risk of Type 1 and Type 2 Myocardial Infarctions Among Adults With HIV (14-05-2018)
Dra. Matilde Sánchez Conde. Infectious Diseases Unit. Hospital Ramón y Cajal, Madrid
Tenofovir alafenamide plus emtricitabine versus abacavir plus lamivudine for treatment of virologically suppressed HIV-1-infected adults: a randomised, double-blind, active-controlled, non-inferiority phase 3 trial (05-05-2018)
Dr. Arkaitz Imaz. Servicio de Enfermedades Infecciosas Hospital Universitario de Bellvitge, Barcelona
Which HIV-infected adults with high CD4 T-cell counts benefit most from immediate initiation of antiretroviral therapy? A post-hoc subgroup analysis of the START trial (16-04-2018)
Dr. Esteban Martínez. Infectious Diseases Unit. Hospital Clínic, University of Barcelona
Disparities in the Quality of Cardiovascular Care Between HIV-Infected Versus HIVUninfected Adults in the United States: A Cross-Sectional Study (02-04-2018)
Dra. Ana Mariño. Unidad de VIH. Hospital Arquitecto Marcide-Novoa Santos, A Coruña.
Non Antiretrocial Polypharmacy and Adverse Health Outcomes Amon HIV. Infected and Uninfected Individuals (15-03-2018)
Dr. Julián Olalla Sierra. Especialista en Medicina Interna Hospital Costa del Sol, Marbella
Efficacy and safety of varenicline for smoking cessation in people living with HIV in France (ANRS 144 Inter-ACTIV): a randomised controlled phase 3 clinical trial (01-03-2018)
Dra. Marta Montero Alonso. Unidad de Enfermedades Infecciosas. Hospital Universitario y Politécnico la Fe, Valencia.
Efficacy, safety, and tolerability of dolutegravir-rilpivirine for the maintenance of virological suppression in adults with HIV-1: phase 3, randomised, non-inferiority SWORD-1 and SWORD-2 studies (15-02-2018)
Dra. Matilde Sánchez Conde. Infectious Diseases Unit. Hospital Ramón y Cajal, Madrid
Switching from a ritonavir-boosted protease inhibitor to a dolutegravir-based regimen for maintenance ofHIV viral suppression in patients with high cardiovascular (01-02-2018)
Dr. Esteban Martínez. Infectious Diseases Unit. Hospital Clínic, University of Barcelona
HIV-1 drug resistance before initiation or re-initiation of first-line antiretroviral therapy in low-income and middle-income countries: a systematic review andmeta-regression analysis (18-01-2018)
Dr. Arkaitz Imaz. Servicio de Enfermedades Infecciosas Hospital Universitario de Bellvitge, Barcelona
Effect of Immediate Initiation of Antiretroviral Treatment in HIV-Positive Individuals Aged 50 Years or Older (01-01-2018)
Dr. Ana Mariño. Unidad de VIH del Hospital Arquitecto Marcide-Novoa Santos
Raltegravir 1200 mg once daily versus raltegravir 400 mg twice daily, with tenofovir disoproxil fumarate and emtricitabine, for previously untreated HIV-1 infection: a randomised, double-blind, parallel-group, phase 3, noninferiority trial (15-12-2017)
Dr. Julián Olalla Sierra. Especialista en Medicina Interna Hospital Costa del Sol, Marbella
Antiretroviral combination use during pregnancy and the risk of major congenital malformations (01-12-2017)
Dra. Marta Montero Alonso. Unidad de Enfermedades Infecciosas Hospital Universitario y Politécnico la Fe, Valencia
Efficacy, safety, and effect on sexual behaviour of on-demand pre-exposure prophylaxis for HIV in men who have sex with men: an observational cohort study (16-11-2017)
Dra. Matilde Sánchez Conde. Infectious Diseases Unit Hospital Ramón y Cajal, Madrid
Long-acting intramuscular cabotegravir and rilpivirine in adults with HIV-1 infection (LATTE-2): 96-week results of randomised, open-label, phase 2b, non-inferiority trial (02-11-2017)
Dr. Arkaitz Imaz. Infectious Diseases Unit Hospital de Bellvitge, Barcelona
Tolerability of Integrase Inhibitors in a Real-Life Setting (16-10-2017)
Dr. Esteban Martínez. Infectious Diseases Unit Hospital Clínic, University of Barcelona
Epidemiology of autoimmune and inflammatory diseases in a French nationwide HIV cohort (02-10-2017)
Dra. Ana Mariño. Unidad de VIH Hospital Arquitecto Marcide-Novoa Santos
Single Dose Versus 3 Doses of Intramuscular Benzathine Penicillin for Early Syphilis in HIV: A Randomized Clinical Trial (15-06-2017)
Dr. Adrian Currán Atencion sanitaria y hospitalaria Hospital Universitari de la Vall d´Hebron
